The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: Clinical experience with anti-angiogenic agents, focusing on bevacizumab

The importance of angiogenesis in tumour growth and development is well known. Overexpression of vascular endothelial growth factor (VEGF), the key mediator of angiogenesis, is associated with poor prognosis in breast cancer. As a result, several therapeutic agents that inhibit the actions of VEGF o...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:European journal of cancer (1990) Ročník 44; číslo 7; s. 912 - 920
Hlavní autori: Marty, Michel, Pivot, Xavier
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: Oxford Elsevier Ltd 01.05.2008
Elsevier
Predmet:
Angiogenesis
Angiogenesis Inhibitors
Angiogenesis Inhibitors - administration & dosage
Angiogenesis Inhibitors - therapeutic use
Anthracyclines
Anthracyclines - administration & dosage
Antibodies, Monoclonal
Antibodies, Monoclonal - administration & dosage
Antibodies, Monoclonal - adverse effects
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Bevacizumab
Biological and medical sciences
Breast cancer
Breast Neoplasms
Breast Neoplasms - drug therapy
Clinical Trials, Phase III as Topic
Female
Hematology, Oncology and Palliative Medicine
Humans
Immunology
Life Sciences
Medical sciences
Monoclonal antibody
Neoplasm Metastasis
Neovascularization, Pathologic
Neovascularization, Pathologic - prevention & control
Paclitaxel
Paclitaxel - administration & dosage
Pharmacology. Drug treatments
Taxoids
Taxoids - administration & dosage
Tumors
Tyrosine kinase inhibitor
Vascular endothelial growth factor (VEGF)
Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factor A - antagonists & inhibitors
Angiogenesis
Breast cancer
Monoclonal antibody
Tyrosine kinase inhibitor
Vascular endothelial growth factor (VEGF)
Bevacizumab
Antineoplastic agent
Breast disease
Enzyme
Transferases
VEGF
Pharmacology
Malignant tumor
Metastasis
Mammary gland diseases
Cancerology
Vascular endothelium growth factor
Treatment
Advanced stage
Inhibitor
Neovascularization
Antiangiogenic agent
Protein-tyrosine kinase
Vascular endothelial growth factor
Cancer
ISSN:0959-8049, 1879-0852
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:The importance of angiogenesis in tumour growth and development is well known. Overexpression of vascular endothelial growth factor (VEGF), the key mediator of angiogenesis, is associated with poor prognosis in breast cancer. As a result, several therapeutic agents that inhibit the actions of VEGF or its receptors are currently in development for use in metastatic breast cancer (MBC). This review describes the function of VEGF in normal and tumour angiogenesis, explores the rationale behind the use of anti-VEGF therapy in MBC and details the therapeutic impact of such agents on tumour vasculature. Clinical data from trials of anti-VEGF agents in MBC are discussed, with a particular focus on the efficacy and safety of bevacizumab, the anti-VEGF agent at the most advanced stage of development in this tumour type. Future potential uses of bevacizumab in breast cancer are introduced.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:0959-8049
1879-0852
DOI:10.1016/j.ejca.2008.01.005